OraSure Technologies (NASDAQ:OSUR) CFO Kenneth Mcgrath Buys 32,300 Shares of Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) CFO Kenneth Mcgrath purchased 32,300 shares of the firm’s stock in a transaction on Friday, March 20th. The stock was bought at an average price of $2.93 per share, for a total transaction of $94,639.00. Following the purchase, the chief financial officer owned 589,562 shares in the company, valued at approximately $1,727,416.66. This represents a 5.80% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

OraSure Technologies Stock Up 4.4%

Shares of OraSure Technologies stock opened at $3.08 on Tuesday. The firm has a market cap of $212.91 million, a price-to-earnings ratio of -3.31 and a beta of 0.88. The business has a 50-day moving average price of $2.86 and a 200-day moving average price of $2.78. OraSure Technologies, Inc. has a twelve month low of $2.08 and a twelve month high of $4.22.

OraSure Technologies (NASDAQ:OSUR) last posted its earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). The firm had revenue of $26.76 million during the quarter, compared to analysts’ expectations of $26.44 million. OraSure Technologies had a negative return on equity of 16.45% and a negative net margin of 59.76%. On average, equities analysts expect that OraSure Technologies, Inc. will post -0.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of OraSure Technologies in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, OraSure Technologies presently has a consensus rating of “Reduce” and an average price target of $3.00.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Quadrature Capital Ltd bought a new stake in OraSure Technologies during the fourth quarter worth approximately $28,000. Prudential Financial Inc. bought a new stake in shares of OraSure Technologies in the 2nd quarter valued at approximately $31,000. L2 Asset Management LLC bought a new stake in shares of OraSure Technologies in the 2nd quarter valued at approximately $39,000. Coldstream Capital Management Inc. boosted its holdings in shares of OraSure Technologies by 128.2% in the 2nd quarter. Coldstream Capital Management Inc. now owns 13,308 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 7,477 shares during the period. Finally, Amundi purchased a new position in shares of OraSure Technologies in the 1st quarter worth approximately $47,000. Institutional investors own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.